Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow

Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma

(2021) Pieter Langerhorst et al.   CLINICAL CHEMISTRY

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

(2021) Benjamin A. Derman et al.   Blood Cancer Journal

Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins

(2020) M Zajec et al.   CLINICAL CHEMISTRY

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins

(2020) Joannes F.M. Jacobs et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis

(2020) Katherine A. Turner et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Mass Spectrometry–Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma

(2020) Carlo O. Martins et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity

(2020) Benjamin T. Diamond et al.   BLOOD REVIEWS

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment

(2020) Katharina Kriegsmann et al.   Cancers

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

(2020) Nikhil C. Munshi et al.   Blood Advances

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

(2020) Caleb Ho et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial

(2019) Ruth De Tute et al.   Clinical Lymphoma Myeloma & Leukemia

Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies

(2018) Marina Zajec et al.   JOURNAL OF PROTEOME RESEARCH

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

(2018) Aurore Perrot et al.   BLOOD

The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics

(2017) Lindsay K. Pino et al.   MASS SPECTROMETRY REVIEWS

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

(2017) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expressed fusion gene landscape and its impact in multiple myeloma

(2017) A. Cleynen et al.   Nature Communications

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Frontline therapy of multiple myeloma

(2015) P. Moreau et al.   BLOOD

New criteria for response assessment: role of minimal residual disease in multiple myeloma

(2015) B. Paiva et al.   BLOOD

MiXCR: software for comprehensive adaptive immunity profiling

(2015) Dmitriy A Bolotin et al.   NATURE METHODS

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

(2015) Sham Mailankody et al.   Nature Reviews Clinical Oncology

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

(2014) A. Brioli et al.   BLOOD

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

(2011) M. Dimopoulos et al.   BLOOD

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted Assembly of Short Sequence Reads

(2011) René L. Warren et al.   PLoS One

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA